Latest News

Latest News

2012
2.2.12	PharmaGap In Vivo Study Results Include Indication of 80% to 88% Reduction in Ascites, 62% Reduction In Tumour Burden in Ovarian Cancer Models
1.20.12	PharmaGap Completes $231,000 Private Placement
1.11.12	PharmaGap Completes $70,774 Private Placement

2011
12.21.11	PharmaGap Completes In Vivo Study Protocol In Ovarian Cancer
12.05.11	PharmaGap Completes $634,210 Private Placement
11.28.11	PharmaGap Completes Initial Closing of Private Placement
11.25.11	PharmaGap Liposomal Formulations Achieve Key Milestones For Clinical Trials
11.15.11	PharmaGap Announces Start of Definitive Animal Efficacy Study Required to Proceed to Clinical Trials
10.27.11	PharmaGap Sets Time For In Vivo Tests
10.24.11	PharmaGap Chooses Ovarian Cancer as Target for First Clinical Trials
10.21.11	PharmaGap Completes Placement of Equity Units
10.19.11	PharmaGap Completes Manufacturer Site Audits Required for Clinical Trial Submission
10.03.11	PharmaGap Files Provisional Patent Application for Liposomal Formulations of GAP-107B8
09.30.11	PharmaGap To Host Investor Conference Call
09.29.11	PharmaGap Adds to Patent Portfolio For GAP-107B8 Cancer Drug; Expands Claims
09.22.11	PharmaGap Completes Initial Close of Private Placement
09.12.11	PharmaGap Announces Successful Completion of Liposomal Development With Significantly Improved Potency of Cancer Drug
08.17.11	PharmaGap Completes Debt Conversion Transaction
08.04.11	PharmaGap Completes $496,405 Private Placement
07.19.11	PharmaGap Completes Arrangements for Bladder Cancer Test Program
07.13.11	PharmaGap Completes Initial Close of Private Placement
06.15.11	PharmaGap Reports Significant Improvement in Efficacy of Enhanced GAP-107B8; Early Results of Testing in Bladder Cancer
05.19.11	PharmaGap Reports Improved Potency and Bioavailability Using Liposome Formulations of GAP-107B8
05.11.11	PharmaGap Announces Conversion of Amounts Owed to Founding Directors Into Common Shares
05.04.11	PharmaGap Reports Significant Progress in Development of Liposomal Formulations of Cancer Drug GAP-107B8
04.18.11	PharmaGap Sees Positive Results from In Vivo Ovarian Cancer Models at the Ottawa Hospital Research Institute
04.05.11	PharmaGap Preparing for Clinical Trials
03.14.11	PharmaGap Announces Completion of Oversubscribed Private Placement, Total Amount Raised $1,034,165
02.24.11	PharmaGap Completes Initial Closing of Private Placement of Equity Units for $835,725 - update
02.23.11	PharmaGap Completes Initial Closing of Private Placement of Equity Units for $835,725
02.11.11	PharmaGap Lead Drug to be Presented at American Association for Cancer Research 102nd Annual Meeting
02.08.11	PharmaGap Announces Contract for Development and Production of Targeted Delivery System for Lead Drug
01.27.11	PharmaGap Provides Clinical Development Program Update